Langrui Medical, China's First Intelligent ECG SaaS Platform, Secures Tens of Millions in Pre-A Funding Led by Panlin Capital

Recently, VCBeat (WeChat ID: vcbeat) learned thatChengdu Langrui Medical Technology Co., Ltd. (hereinafter referred to as “Langrui Medical”) has completed a pre-A round of financing amounting to tens of millions of yuan,Panlin Capital led the investment.

Langrui Medical is China’s first intelligent ECG diagnosis platform, with its founding team having accumulated years of experience and research in the fields of clinical electrocardiography and online platforms.

The team’s independently developed ECG analysis SaaS system is compatible with various ECG monitoring hardware devices. Leveraging proprietary artificial intelligence (AI) algorithms, it identifies, processes, and categorizes the massive volumes of ECG data recorded by these devices. This liberates physicians from tedious and mechanical tasks such as artifact removal, thereby enhancing the efficiency of ECG specialists and reducing patient wait times. The system effectively supports collaborative ECG diagnostics between primary care hospitals and tertiary referral centers, while also driving growth for equipment manufacturers. This “multi-party benefit” model has broken through industry development bottlenecks and optimized the traditional landscape of ECG diagnostics in China.

In China, the prevalence of cardiovascular diseases is extremely high, with screening and diagnosis primarily relying on examinations such as electrocardiography (ECG). Among these, ambulatory ECG monitoring, which continuously records a patient’s 24-hour ECG during daily activities, plays a significant role in diagnosing occult, paroxysmal, or complex cardiovascular conditions. According to data provided by the Chinese Tele-ECG Diagnosis Group in 2015, 250 million routine ECG examinations and 35 million ambulatory ECG examinations are performed annually in China.

Previously, such vast amounts of examination data relied heavily on manual correction by physicians. In particular, the algorithms in legacy dynamic ECG software were relatively outdated, resulting in significant classification errors. This not only consumed substantial physician effort but also prolonged patient appointment wait times.

Leveraging its profound understanding of electrocardiogram (ECG) business processes, Langrui Medical has entered the ECG healthcare sector with an ECG SaaS system that aligns with physicians’ diagnostic workflows, thereby enhancing efficiency for both doctors and patients and helping physicians streamline hospital ECG examination procedures.

From the perspective of Panlin Capital’s healthcare investment team, Langrui’s ECG SaaS system serves as both an efficiency-enhancing tool and an empowering platform. Driven by the team’s efforts, the system has been deployed in primary care hospitals to collect patients’ ECG data, which is then transmitted to higher-level hospitals. This model not only helps primary care institutions generate additional revenue but also ensures that patients receive effective and timely diagnosis and treatment, aligning with China’s national policy direction on tiered diagnosis and treatment. As a large number of doctors and patients converge on the platform, it is gradually becoming the primary gateway for ECG data in China, filling the current gap in medical ECG data and serving as an indispensable component of big data in healthcare. Against the backdrop of trends toward healthcare informatization and interoperability of medical data, the company’s value will become increasingly prominent.

Indeed, propelled by national policies, the field of big data in healthcare is flourishing. Numerous industry giants and medical institutions have entered this space. Langrui Medical has entered the electrocardiogram (ECG) diagnosis and treatment sector through its SaaS software, gradually completing its health big data portfolio. This approach holds significant value for clinical decision support, preventive management, new drug development, and basic research in cardiovascular diseases.

Liu Zhusong, founder of Langrui Medical, has dedicated many years to the electrocardiogram (ECG) field, with extensive experience spanning the entire lifecycle of ECG product research and development, manufacturing, and sales. He has witnessed the evolution of ECG technology in China. Discussing the project, Liu stated, “Cardiovascular diagnosis and treatment have long been constrained by software limitations. We hope that Langrui’s ECG SaaS system will truly empower physicians to benefit patients, establish the infrastructure for future new-style healthcare, and drive innovation across the entire ECG sector.”

This is an innovative early-stage investment project by Panlin Capital in the healthcare sector. Li Yuhui, Founding Managing Partner of Panlin Capital, stated, “Dynamic electrocardiography (ECG) is a highly specialized niche within healthcare. Teams that possess both a deep understanding of clinical ECG diagnostic scenarios and expertise in software algorithm development are extremely scarce. Langrui stands out in the industry by combining ‘excellent product managers with top-tier algorithm engineers.’ Panlin Capital is optimistic that its products and services will transform the current industry landscape, serve primary-care hospitals, and improve physicians’ diagnostic efficiency. We also anticipate enhanced value from its ECG data. This investment marks Panlin Capital’s flagship initiative for the year in the B2B healthcare sector.”